Can I read Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP) on EtoBox?

Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP) by Arthur H. Rossof; Robert E. Slayton; Dr. Charles P. Perlia is a Medicine article available to read on EtoBox.

What is Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP) about?

Thirty-one patients with metastatic cancer were treated with ris-diamminedichloroplatinum (11), CACP, in dosages ranging from 7.5 to 200 mg/m' BSA per course. Twenty-two patients received more than one course. Toxicity to the initial course of CACP, up to 90 mg/m2 BSA, was minimal a n d transient in most patients. At higher dosage levels or following repeat courses, the drug-related toxicity was more severe. Drugrelated toxicity was more severe in patients with abnormal excretory tracts. T h e most common and carliest side effects were nausea and vomiting. Hyperuricemia commonIy occurred shortly after administration of CACP. A dosage-dependent, generally transient, nephrotoxicity was noted within the first 10 days after a course o f CACP. Moderate leukopenia a n d thrombocytopenia, as well as a progressive normocytic anemia with marrow erythroid hypoplasia, were observed as late as 3 to 4 weeks after injection of this agent. Audiologic impairment above the frequency range of normal speech was detected by audiometry. Objective tumor regression was seen in five patients, four of whom experienced moderate-to-severe toxicity. OSENBERG ET AI.. OUSEKVED A TKANSFOKMA-R tion to the filamen

Who reads Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP)?

Author

Arthur H. Rossof; Robert E. Slayton; Dr. Charles P. Perlia

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)

Published

1972

Language

EN

Field

Medicine (Health Sciences)